Arcutis Biotherapeutics ARQT
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$19.82M (9 inflow days, 11 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 45.4% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 11.71% to 14.45% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| BlackRock | Mutual Fund | 2026/Q3 | +8,625,569 | 15.2% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +2,200,038 | 4.6% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +1,895,788 | 6.1% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +1,388,692 | 3.0% |
| Simplify Asset Management Inc. | Mutual Fund | 2026/Q3 | +865,862 | 0.7% |
| Morgan Stanley | Public Company | 2026/Q3 | +845,518 | 4.2% |
| Public Sector Pension Investment Board | Government Pension Fund | 2026/Q3 | +774,309 | 0.6% |
| Principal Global Investors, LLC | Mutual Fund | 2026/Q3 | +619,863 | 0.6% |
| Jupiter Fund Management Plc | Mutual Fund | 2026/Q3 | +507,105 | 0.6% |
| Renaissance Technologies Corp. | Hedge Fund | 2026/Q3 | +417,700 | 0.4% |
| OrbiMed Advisors LLC | VC/PE Fund | 2026/Q3 | +2,042,000 | 1.6% |
| D. E. Shaw & Co., L.P. | Hedge Fund | 2026/Q3 | +1,453,387 | 3.1% |
| BlackRock | Mutual Fund | 2026/Q3 | +1,345,055 | 8.4% |
| Citadel Advisors LLC | Hedge Fund | 2026/Q3 | +1,144,408 | 0.9% |
| Jones Hill Capital LP | Hedge Fund | 2026/Q3 | +1,089,701 | 0.9% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 3 Nov 2026 | Robert Lisicki | Interim Executive VP & Chief Commercial Officer | Initial Statement of Beneficial | +0 | – | 55,000 |
| 3 Nov 2026 | Masaru Matsuda | Executive Vice President | Derivative Exercise and Sale | -40,000 | $34.32 | 27,214 |
| 1 Nov 2026 | Todd Watanabe | Chief Executive Officer | Open Market Disposition | -4,377 | $31.86 | 636,660 |
| 1 Nov 2026 | Patrick Burnett | Chief Medical Officer | Open Market Disposition | -943 | $31.86 | 116,649 |
| 1 Nov 2026 | Masaru Matsuda | Executive Vice President | Open Market Disposition | -1,219 | $31.86 | 27,214 |
| 22 Oct 2026 | Robert Andrew Scott | Independent Director | Other Acquisition | +2,819 | – | 2,819 |
| 22 Oct 2026 | Robert Andrew Scott | Independent Director | Other Derivative Acquisition | +29,170 | $31.20 | 8,663 |
| 22 Oct 2026 | Robert Andrew Scott | Independent Director | Initial Statement of Beneficial | +0 | – | 17,523 |
| 14 Oct 2026 | Howard Welgus | Independent Director | Automatic Disposition | -634 | $26.93 | 29,429 |
| 14 Oct 2026 | Howard Welgus | Independent Director | Derivative Exercise and Sale | -4,094 | $26.93 | 29,429 |
| 15 Sep 2026 | Masaru Matsuda | Executive Vice President | Open Market Disposition | -3,674 | $25.00 | 24,889 |
| 14 Sep 2026 | Howard Welgus | Independent Director | Automatic Disposition | -634 | $24.18 | 30,063 |
| 14 Sep 2026 | Howard Welgus | Independent Director | Derivative Exercise and Sale | -4,096 | $24.18 | 30,063 |
| 7 Sep 2026 | Masaru Matsuda | Executive Vice President | Automatic Disposition | -9,989 | $25.03 | 28,563 |
| 26 Aug 2026 | Terrie Curran | Independent Director | Derivative Exercise and Sale | -38,200 | $25.03 | 10,139 |
| 19 Aug 2026 | Terrie Curran | Independent Director | Derivative Exercise and Sale | -1,072 | $26.04 | 10,139 |
| 18 Aug 2026 | Patrick Burnett | Chief Medical Officer | Open Market Disposition | -1,697 | $27.00 | 117,592 |
| 16 Aug 2026 | Howard Welgus | Independent Director | Automatic Disposition | -634 | $26.18 | 30,697 |
| 16 Aug 2026 | Howard Welgus | Independent Director | Derivative Exercise and Sale | -4,096 | $26.18 | 30,697 |
| 11 Aug 2026 | Patrick Burnett | Chief Medical Officer | Derivative Exercise and Sale | -15,000 | $26.52 | 119,289 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 18,157,145 | 14.4% | 7.6 |
| 15 Oct 2026 | 20,485,453 | 16.3% | 9.8 |
| 30 Sep 2026 | 21,688,918 | 17.3% | 4.8 |
| 15 Sep 2026 | 18,458,091 | 14.7% | 8.5 |
| 31 Aug 2026 | 16,557,048 | 13.2% | 9.4 |
| 14 Aug 2026 | 14,717,905 | 11.7% | 8.0 |
No comments yet — be the first to weigh in on ARQT.
Sign in to join the discussion.